pa旗舰厅

 
 
20 publications in total
Clinical Cancer Research
May, 2025
Nature Medicine
Jan, 2025
ASCO Gastrointestinal Cancer Symposium
Jan, 2025
Preliminary Results of Patients with Myelofibrosis from a Phase I Trial of JAB-8263, a potent BET Inhibitor
2024 ASH (American Society of Hematology) Annual Meeting
Dec, 2024
Pre-clinical Data of SHP2 Inhibitor JAB-3312 in combo with KRAS G12C Inhibitor Glecirasib
the Fifth RAS Initiative Symposium 2024
Oct, 2024
Efficacy Data of Glecirasib in Combination with JAB-3312 with PD-L1 Expression Levels
2024 ESMO
Sep, 2024
2024 ASCO
Jun, 2024
2024 ASCO
Jun, 2024
2024 EHA
Jun, 2024
2024 ASCO
May, 2024
JAB-26766: a small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity
2024 AACR Annual Meeting
Apr, 2024
JAB-30355: A highly potent, orally bioavailable p53 Y220C reactivator
2024 AACR Annual Meeting
Apr, 2024
2024 ASCO GI
Jan, 2024
Glecirasib (KRAS G12C Inhibitor) in Combination with JAB-3312 (SHP2 Inhibitor) in Patients with KRAS p.G12C Mutated Solid Tumors
2023 ESMO
Oct, 2023
Glecirasib (JAB-21822, KRAS G12C inhibitor) Monotherapy and in Combination with Cetuximab in Patients with Advanced Colorectal Cancer
2023 JCA-AACR Precision Cancer Medicine International Conference
Jun, 2023
JAB-X1800: a potent immunostimulatory antibody-drug conjugate (iADC) targeting CD73
2023 AACR Annual Meeting
Apr, 2023
JAB-2485: a potent, highly selective small-molecule Aurora kinase A inhibitor that targets cell division
2023 AACR Annual Meeting
Apr, 2023
Preclinical investigation of orally bioavailable, potent KRASmulti inhibitor JAB-23425
2023 AACR Annual Meeting
Apr, 2023
Results of KRAS G12C inhibitor Glecirasib as a single agent or in combination with SHP2 inhibitor JAB-3312
2022 European Society of Medical Oncology ASIA (ESMO ASIA)
Dec, 2022
2022 annual meeting of American Society of Clinical Oncology (ASCO)
Jun, 2022

Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD.